Canada _ (Commonwealth Union) _ Health Canada has initiated a safety study of the psychological withdrawal symptoms linked with discontinuing or lowering the usage of a medicine routinely recommended to assist mothers in breastfeeding.
Domperidone is licensed to treat gastrointestinal problems in Canada. Although it has never been approved by Health Canada for use as a breastfeeding aid, it is routinely administered for this reason off-label.
An investigation also discovered that some doctors prescribe domperidone to encourage breastfeeding at levels three to five times greater than what is suggested by both Health Canada and the medication manufacturer. Because this is not an approved usage or dose anywhere in the world, no large-scale clinical trials have been conducted to provide light on how frequently these adverse effects occur.
There are, however, case studies demonstrating the withdrawal symptoms, including three published in the peer-reviewed journal Breastfeeding Medicine in November 2022. Domperidone inhibits dopamine receptors in the brain, causing prolactin to be released. The authors emphasize that this stimulates lactation, but it can also lead domperidone to operate as an antipsychotic. The scientists also noticed that when women take off the medicine gradually, withdrawal symptoms are often less severe.
The most recent case studies are from the United States, where domperidone is not licensed for any use by the Food and Drug Administration. According to the investigation, some American women obtain the medicine from physicians in Canada.
Following a review, Health Canada may seek further information, research, or monitoring by the manufacturer. They can also result in warnings to patients and health care professionals, changes to how a medicine is labeled, or, if required, the withdrawal of a drug from the market “if the benefits no longer outweigh the hazards of the product,” according to the department’s statement.
